Latigo Biotherapeutics

Update in progress

LTGO (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines that aim to stop pain transmission without addiction risk. Its pipeline centers on NaV1.8 inhibitors: LTG-001, an oral agent for fast-acting, opioid-sparing relief in acute pain; LTG-321, for chronic musculoskeletal pain starting with osteoarthritis; and LTG-418 for both acute and chronic pain. Formerly WVB-Desmond, it renamed Latigo in March 2019. Established in 2018, based in Thousand Oaks, California.

Company score

Sentiment: 0.41; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.17; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive